Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell

STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger...
September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate...
August 29, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari – juni 2025

STOCKHOLM – den 29 augusti 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – juni 2025. Den fulla rapporten är tillgänglig på bolagets hemsida. ...
August 29, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report - January-June 2025

STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. “We have a...
August 28, 2025 07:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics tillförs 28,3 miljoner kronor i övertecknad företrädesemission av units

STOCKHOLM, 28 augusti 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics tillförs 28,3 miljoner kronor i en företrädesemission av units som...
August 28, 2025 07:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue

STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a...
July 14, 2025 11:01 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 24,6 miljoner till den pågående kliniska utvecklingen av golexanolon

STOCKHOLM, 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har genomfört en kapitalanskaffning om SEK 24,6 miljoner genom ett...
July 14, 2025 11:01 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone

STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible...
July 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics har slutfört rekryteringen i del 1 av sin fas 2a-studie med sevuparin

STOCKHOLM, SVERIGE 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har slutfört patientrekryteringen enligt tidsplan till del 1 av...
July 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin

STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1...